FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & Co.’s Keytruda.